Rybrevant (amivantamab) - originally developed by Danish biotech Genmab – has been cleared for NSCLC patients with exon 20 insertions, the third most common EGFR mutation in this form of lung ...

Johnson & Johnson’s Rybrevant is on the brink of EU approval as a treatment for a subset of patients with newly diagnosed EGFR-positive lung cancer, after a recommendation from the EMA’s Human ...

Researchers conducting this trial will compare zipalertinib plus chemotherapy with chemotherapy alone in patients with previously untreated, locally advanced or metastatic non-small cell lung cancer ...

Pharmacogenomics. 2009;10(1):59-68.

002030.SZ Daan Gene Co., Ltd.

002030.SZ Daan Gene Co., Ltd.

随着精准医学发展，肿瘤中的驱动靶点不断被发现，针对这些靶点的靶向治疗也显著改善了患者预后。自 2004 年开始，MET 基因异常开始逐渐走入研究视野，然而其靶向治疗却一路曲折。历经数年研发，随着越来越多 MET 抑制剂的出现，MET ...

If you're interested in exploring more stocks under $20 get an edge over other traders with Benzinga Pro while we're currently offering a 14-day trial. Stocks under $20 offer investors and ...

Detailed price information for Oric Pharmaceuticals Inc (ORIC-Q) from The Globe and Mail including charting and trades.

NSCLC治疗手段不断革新，一文为您解读！肺癌是全球范围内最常见的恶性肿瘤之一，其中非小细胞肺癌（NSCLC）约占肺癌病例的85%[1]。作为医学界的重点研究对象之一，NSCLC的治疗涉及多种手段，从手术到放射治疗，再到化疗、免疫治疗、靶向治疗，随着各种诊疗方法的不断进步，也为NSCLC患者的生存预后提供了更多可能性和机会。